Home » Newsletters » BioWorld Science

BioWorld Science

July 24, 2002

View Archived Issues

Vertex offers progress report for first half of 2002

Polymeric viral attachment inhibitor protects against influenza infection

FDA advisory committee decisions regarding two BMS drugs

Inositol may play a role in preventing Abeta plaque formation and cognitive dysfunction in AD

Pilot study provides basis for further clinical evaluation of CX-516 in dementia

Upregulation of NGF may account for the neuroprotective effects of dexefaroxan

Neuroprotective CB1 receptor agonist in development at Bayer

Differential binding and functional profile at ETA/ETB receptors described for Novartis compound

New CDK inhibitors identified at BMS

Carbapenem antibiotics identified by Sumitomo scientists

Pola Chemical presents multidrug resistance modulators for use in microbial infections

Uroselective alpha1A-adrenoceptor antagonists and their use in BPH described by Ranbaxy

Bayer patent covers IKK-beta inhibitors for use in asthma and other disorders

Novel SGLT2 inhibitors in early development at Kissei

Dual 5-HT1A antagonists/5-HT reuptake inhibitors disclosed in Mitsubishi Pharma patent

ENO gas has beneficial effects in neonatal persistent pulmonary hypertension

Sitaxsentan phase IIb/III trial completes enrollment, extension study stopped

MT-300 meets primary endpoint in phase III migraine trial

CP-461 enters phase II pilot trial in Crohn's disease

Oncophage designated orphan drug for metastatic melanoma

Aged garlic extract lessens streptozotocin-induced cognitive decline in rats

British Biotech and BresaGen terminate E21R development agreement

Pyridorin granted fast track status for diabetic nephropathy

Enrollment completed in phase II/III trial of ABX-CBL in steroid-resistant GVHD

OGS and Cystic Fibrosis Foundation Therapeutics enter CF proteomics research collaboration

Spotlight on antiamyloid therapeutic strategies reported in Stockholm

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...